Top

Published in:

01-10-2012 | Letter to Editor

Primitive Neuroectodermal Tumor of Ovary in a Young Lady, Confirmed with Molecular and Cytogenetic Results—A Rare Case Report with a Diagnostic and Therapeutic Challenge

Authors: Vikas Ostwal, Bharat Rekhi, Vanita Noronha, Ranjan Basak, Sangeeta B. Desai, Amita Maheshwari, Kumar Prabhash

Published in: Pathology & Oncology Research | Issue 4/2012

Excerpt

Primitive neuroectodermal tumor (PNET) is a small round cell tumor of neuroectodermal origin. It is the most differentiated form of PNET/Ewing’s family of tumors (EFT) [1]. It is the second most common sarcoma among children and usually occurs in the bone and soft tissues [2]. Ewing’s sarcoma/PNET is characterized by a t (11; 22) (q24; q12) chromosomal translocation that leads to formation of a chimeric transcript EWS-FLI1 in 85% cases, presence of which confirms its diagnosis, especially at non-conventional sites [3]. It has been uncommonly documented at sites other than musculoskeletal system, such as kidneys [4]. PNET has been rarely documented in the female genital system, including ovary, with only few cases confirmed by molecular and / or molecular cytogenetic analysis [5‐12]. …

Available only for authorised users

Enzinger FM, Weiss SW (1995) Primitive neuroectodermal tumors and related lesions. In: Enzinger FM, Weiss SW (eds) Soft tissue tumors, 3rd edn. Mosby-Year Book, St Louis, pp 929–964

Grier HE (1997) The Ewing family of tumors: Ewing’s sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 44:991–1004PubMedCrossRef

Aurias A, Rimbaut C, Buffe D, Dubousett MA (1983) Chromosomal translocations in Ewing’s sacoma. New Eng J Med 309:496–497

Marley EF, Liapis H, Humphrey PA (1997) Primitive neuroectodermal tumor of the kidney-another enigma: a pathologic, immunohistochemical, and molecular diagnostic study. Am J Surg Pathol 21:354–359PubMedCrossRef

Rekhi B, Qureshi S, Basak R, Menon S, Desai S, Medhi S, Kurkure P, Maheshwair AM, Jambhekar NA (2010) A primary vaginal Ewing’s sarcoma/Primitive neuroectodermal tumor (PNET) in a young girl with t (11; 22) (q24; q12) (EWSR1-FLI1) positive results: a case report. J Med Case Report 4:88CrossRef

Lawlor ER, Murphy JI, Sorensen PH, Fryer CJ (1997) Metastatic primitive neuroectodermal tumour of the ovary: successful treatment with mega-dose chemotherapy followed by peripheral blood progenitor cell rescue. Med Pediatr Oncol 29:308–312PubMedCrossRef

Kawauchi S, Fukuda T, Miyamoto S, Yoshioka J, Shirahama S, Saito T, Tsukamoto N (1998) Peripheral primitive neuroectodermal tumor of the ovary confirmed by CD99 immunostaining, karyotypic analysis, and RT-PCR for EWS/FLI-1 chimeric mRNA. Am J Surg Pathol 22:1417–1422PubMedCrossRef

Shigeto K, Toshiro F, Shingo M, Jun-Ichi Y, Syuya S, Toshiaki S (1998) Peripheral primitive neuroectodermal tumor of the ovary confirmed by CD99 immunostaining, karyotypic analysis and RT-PCR for EWS/FLI-1 chimeric mRNA. Am J Surg Pathol 22:1417–1422CrossRef

Rangan A, Lobo FD, Rao AA (2003) Primary primitive neuroectodermal tumor of the ovary: a case report. Indian J Pathol Microbiol 46:58–59PubMed

10.

Kim KJ, Jang BW, Lee SK, Kim BK, Nam SL (2004) A case of peripheral primitive neuroectodermal tumor of the ovary. Int J Gynecol Cancer 14:370–372PubMedCrossRef

11.

Ateser G, Yildiz O, Leblebici C, Mandel NM, Unal F, Turna H, Arikan I, Colcaki D (2007) Metastatic primitive neuroectodermal tumor of the ovary in pregnancy. Int J Gynecol Cancer 17:266–269PubMedCrossRef

12.

Chow SN, Lin MC, Shen J, Wang S, Jong YJ, Chien CH (2004) Analysis of chromosome abnormalities by comparative genomic hybridization in malignant peripheral primitive neuroectodermal tumor of the ovary. Gynecol Oncol 92:752–760PubMedCrossRef

13.

Bridge RS, Rajaram V, Dehner LP, Pfeifer JD, Perry A (2006) Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors. Mod Pathol 19:1–8PubMedCrossRef

14.

Kleinman GM, Young RH, Scully RE (1993) Primary neuroectodermal tumors of the ovary. A report of 25 cases. Am J Surg Pathol 17:764–778PubMedCrossRef

15.

Anfinan NM, Sait KH, Al-Maghrabi JA (2008) Primitive neuroectodermal tumor of the ovary. Saudi Med J 29:444–446PubMed

16.

Ambros IM, Ambros PF, Strehl S, Kovar H, Gardner H, Salzer-Kuntschik M (1991) MIC2 is a specific marker for Ewing’s sarcoma and peripheral primitive neuroectodermal tumors. Cancer 67:1886–1893PubMedCrossRef

17.

Gordon MD, Corless C, Renshaw AA, Beckstead J (1998) CD99, keratin, and vimentin staining of sex cord-stromal tumors, normal ovary, and testis. Mod Pathol 11:769–773PubMed

18.

Lin PP, Brody RI, Hamelin AC, Bradner JE, Healey JH, Ladanyi M (1999) Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing’s sarcoma. Cancer Res 59:1428–1432PubMed

19.

Giovannini M, Biegel JA, Serra M, Wang JY, Wei YH, Nycum L, Emanuel BS, Evans GA (1994) EWS-erg and EWS-Fli1 fusion transcripts in Ewing’s sarcoma and primitive neuroectodermal tumors with variant translocations. J Clin Invest 94:489–496PubMedCrossRef

20.

Kovar H, Aryee DN, Jug G, Henockl C, Schemper M, Delattre O, Thomas G, Gadner H (1996) EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 7:429–437PubMed

21.

Toretsky JA, Connell Y, Neckers L, Bhat NK (1997) Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 31:9–16PubMedCrossRef

22.

Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y (1997) EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing’s sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 99:239–247PubMedCrossRef

Title: Primitive Neuroectodermal Tumor of Ovary in a Young Lady, Confirmed with Molecular and Cytogenetic Results—A Rare Case Report with a Diagnostic and Therapeutic Challenge
Authors: Vikas Ostwal
Bharat Rekhi
Vanita Noronha
Ranjan Basak
Sangeeta B. Desai
Amita Maheshwari
Kumar Prabhash
Publication date: 01-10-2012
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-012-9503-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2012

Increased Expression of FAT10 is Correlated with Progression and Prognosis of Human Glioma

Whey Protein Versus Whey Protein Hydrolyzate for the Protection of Azoxymethane and Dextran Sodium Sulfate Induced Colonic Tumors in Rats

Oncolytic Viruses in the Treatment of Cancer: A Review of Current Strategies

Primary Esophageal Small Cell Carcinoma with Brain Metastasis and with CD56, KIT, and PDGFRA Expressions

Menthol Inhibits the Proliferation and Motility of Prostate Cancer DU145 Cells

Desmoplastic Small Round Cell Tumor-Clinicopathological Spectrum, Including Unusual Features and Immunohistochemical Analysis of 45 Tumors Diagnosed at a Tertiary Cancer Referral Centre, with Molecular Results t(11; 22) (p13; q12) (EWS-WT1) in Select Cases

Keynote webinar | Spotlight on antibody–drug conjugates in cancer